Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Trastuzumab pamirtecan by BioNTech for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Trastuzumab pamirtecan is under clinical development by BioNTech and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...
Data Insights
Trastuzumab pamirtecan by BioNTech for Solid Tumor: Likelihood of Approval
Trastuzumab pamirtecan is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase...